Lawsuits filed over U.S. state restrictions on abortion pills

[January 26, 2023]  By Jonathan Stempel and Brendan Pierson

(Reuters) -A maker of abortion pills and a doctor have filed lawsuits challenging state restrictions on the medication, in the first lawsuits of their kind since the U.S. Supreme Court overturned the federal constitutional right to abortion.

In a complaint filed in federal court in Huntington, West Virginia, GenBioPro Inc said the state cannot override the U.S. Food and Drug Administration (FDA) approval from 2000 of mifepristone by banning the drug, the first in a two-drug regimen for medication abortions.

The doctor, Amy Bryant, filed a separate lawsuit in the federal court in Durham, North Carolina, challenging state-imposed restrictions on obtaining mifepristone, which she said impeded her ability to treat patients.

Both lawsuits fuel a growing legal battle over medication abortion in the wake of the U.S. Supreme Court's June ruling eliminating the longstanding right to abortion established 50 years ago in Roe v. Wade, and effectively left states to regulate the procedure.
 

In a separate case, anti-abortion activists are urging a Texas federal judge to undo FDA approval of mifepristone altogether, and effectively pull the drug off the market.

Medication abortions make up more than half of U.S. abortions. Misoprostol is the second drug of the two-drug regimen for medication abortions.

GenBioPro, which sells a generic version of mifepristone, said West Virginia's Unborn Child Protection Act, which banned nearly all abortions in September, "conflicts with the strong national interest in ensuring access to a federally approved medication to end a pregnancy."

According to the lawsuit, the abortion pill ban violated the U.S. Constitution's Supremacy Clause because Congress gave the FDA the power to regulate drugs. The clause gives federal laws priority over conflicting state laws.

GenBioPro also said that the state's ban violated the Constitution's Commerce Clause, which restricts states from burdening interstate commerce.

U.S. Attorney General Merrick Garland said last June that states "may not ban mifepristone based on disagreement with the FDA's expert judgment about its safety and efficacy."

A pack of Mifeprex pills, used to terminate early pregnancies, is displayed in this picture illustration taken May 11, 2022. REUTERS/Caitlin Ochs/Illustration

Bryant objected to North Carolina's requirements that patients obtain abortion pills only in person from physicians in specially certified facilities, and undergo state-mandated counseling at least 72 hours before having abortions.

Her lawsuit said the restrictions "interfere with her ability to provide medical care to her patients according to her best medical judgment and in accordance with federal law."

"We are prepared to defend West Virginia's new abortion law to the fullest," West Virginia Attorney General Patrick Morrisey, a Republican, said in a statement.

A spokeswoman for North Carolina Attorney General Josh Stein, a Democrat, said the state was reviewing Bryant's complaint.

GenBioPro previously sued Mississippi over restrictions on mifepristone there, but dropped the case in August after the state banned nearly all abortions following the Supreme Court's decision. The company cited a "changed national landscape" for its decision.

Twelve states, all of which have Republican governors and legislatures, now ban nearly all abortions, including medication abortions.

As of November, 16 states that permit some abortions, including North Carolina, restrict medication abortion to some extent, according to the Guttmacher Institute, a research group that supports abortion rights.

The cases are GenBioPro Inc v Sorsaia et al, U.S. District Court, Southern District of West Virginia, No. 23-00058; and Bryant v Stein et al, U.S. District Court, Middle District of North Carolina, No. 23-00077.

(Reporting by Jonathan Stempel and Brendan Pierson in New YorkEditing by Tomasz Janowski, Alexia Garamfalvi and Howard Goller)

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.